Jennifer Mitchell, PhD, an associate professor of neurology in the UCSF School of Medicine, is researching the hormone oxytocin as a potential therapy to help soldiers who are suffering from PTSD and alcohol abuse disorder. The clinical trial is taking place at a mental health facility at Fort Gordon in Augusta, GA.
After a 40 year odyssey, the first drug to treat aggressive multiple sclerosis has won FDA approval. It grew out of the work of Dr. Stephen Hauser, chair of neurology at UCSF, whose team persevered for decades and defended their findings that contradicted long-standing assumptions. Ocrelizumab is the first MS drug that targets B cells in the human body.
Dr. Bruce Miller, Professor of Neurology and Director of the UCSF Memory and Aging Center, has been awarded the 2017 Holly Smith Award for Exceptional Service to the School of Medicine. He was also recently elected to the National Academy of Medicine (formerly the Institute of Medicine).
The largest single gift ever to UCSF, a $185 million donation from Sanford I. “Sandy” Weill and Joan Weill, has launched the UCSF Weill Institute for Neurosciences. This new institute will provide resources to our neuroscience researchers and physicians to advance our knowledge and treatment options for diseases affecting the brain and nervous system, including psychiatric disorders.
S. Andrew Josephson, M.D., professor and senior executive vice chair of the UCSF Department of Neurology, has been named the next editor-in-chief of JAMA Neurology, one of 12 journals in the JAMA Network. “I am tremendously excited about this opportunity and welcome the chance to join the JAMA family and continue the incredible record of excellence that Roger Rosenberg set during his 20 years as editor,” said Dr. Josephson. Read more here.